168 related articles for article (PubMed ID: 7066021)
1. Pharmacokinetics of inhibition of adenosine deaminase by erythro-9-(2-hydroxy-3-nonyl)adenine in CBA mice.
Lambe CU; Nelson DJ
Biochem Pharmacol; 1982 Feb; 31(4):535-9. PubMed ID: 7066021
[TBL] [Abstract][Full Text] [Related]
2. Adenosine deaminase inhibitors. Synthesis of deaza analogues of erythro-9-(2-hydroxy-3-nonyl)adenine.
Antonini I; Cristalli G; Franchetti P; Grifantini M; Martelli S; Lupidi G; Riva F
J Med Chem; 1984 Mar; 27(3):274-8. PubMed ID: 6699873
[TBL] [Abstract][Full Text] [Related]
3. Sedative and electroencephalographic actions of erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA): relationship to inhibition of brain adenosine deaminase.
Mendelson WB; Kuruvilla A; Watlington T; Goehl K; Paul SM; Skolnick P
Psychopharmacology (Berl); 1983; 79(2-3):126-9. PubMed ID: 6405420
[TBL] [Abstract][Full Text] [Related]
4. Effect of chirality in erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA) on adenosine deaminase inhibition.
Bessodes M; Bastian G; Abushanab E; Panzica RP; Berman SF; Marcaccio EJ; Chen SF; Stoeckler JD; Parks RE
Biochem Pharmacol; 1982 Mar; 31(5):879-82. PubMed ID: 7082355
[No Abstract] [Full Text] [Related]
5. Inhibition of human T-cell rosette formation by the adenosine deaminase inhibitor erythro-9-(2-hydroxy-3-nonyl) adenine hydrochloride (EHNA).
Lum CT; Schmidtke JR; Sutherland DE; Najarian JS
Clin Immunol Immunopathol; 1978 Jul; 10(3):258-61. PubMed ID: 307473
[No Abstract] [Full Text] [Related]
6. Adenosine deaminase inhibitors. Synthesis and biological activity of deaza analogues of erythro-9-(2-hydroxy-3-nonyl)adenine.
Cristalli G; Franchetti P; Grifantini M; Vittori S; Lupidi G; Riva F; Bordoni T; Geroni C; Verini MA
J Med Chem; 1988 Feb; 31(2):390-3. PubMed ID: 3339608
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of adenosine deaminase from several sources by deaza derivatives of adenosine and EHNA.
Lupidi G; Cristalli G; Marmocchi F; Riva F; Grifantini M
J Enzyme Inhib; 1985; 1(1):67-75. PubMed ID: 3916912
[TBL] [Abstract][Full Text] [Related]
8. Effects of the chiral isomers of erythro- and threo-9-(2-hydroxy-3-nonyl)adenine on purine metabolism in sarcoma 180 cells.
Chen SF; Stoeckler JD; Choi HS; Burgess FW; Marcaccio EJ; Steen PA; Berman SF; Parks RE; Panzica RP; Abushanab E
Biochem Pharmacol; 1982 Dec; 31(24):3955-60. PubMed ID: 7159473
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of PHA and NaI04 mitogenesis by the adenosine deaminase inhibitors erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA) and 2-deoxycoformycin (2-dCF).
Lum CT; Sutherland DE; Najarian JS
Clin Immunol Immunopathol; 1979 Apr; 12(4):453-9. PubMed ID: 222523
[No Abstract] [Full Text] [Related]
10. The protonated form of 1-N6-etheno-[erythro-9-(2-hydroxy-3-nonyl)] adenine is identified at the active site of adenosine deaminase.
Caiolfa VR; Gill D; Parola AH
FEBS Lett; 1990 Jan; 260(1):19-22. PubMed ID: 2153576
[TBL] [Abstract][Full Text] [Related]
11. Kinetics of inhibition of calf intestinal adenosine deaminase by (+)- and (-)-erythro-9-(2-hydroxy-3-nonyl)adenine.
Porter DJ; Abushanab E
Biochemistry; 1992 Sep; 31(35):8216-20. PubMed ID: 1525161
[TBL] [Abstract][Full Text] [Related]
12. Adenosine deaminase inhibitors. Synthesis and biological evaluation of putative metabolites of (+)-erythro-9-(2S-hydroxy-3R-nonyl)adenine.
Vargeese C; Sarma MS; Pragnacharyulu PV; Abushanab E; Li SY; Stoeckler JD
J Med Chem; 1994 Oct; 37(22):3844-9. PubMed ID: 7966142
[TBL] [Abstract][Full Text] [Related]
13. Erythro-9-(2-hydroxy-3-nonyl)adenine as a specific inhibitor of herpes simplex virus replication in the presence and absence of adenosine analogues.
North TW; Cohen SS
Proc Natl Acad Sci U S A; 1978 Oct; 75(10):4684-8. PubMed ID: 216993
[TBL] [Abstract][Full Text] [Related]
14. Adenosine uptake and deamination regulate tonic A2a receptor facilitation of evoked [3H]acetylcholine release from the rat motor nerve terminals.
Correia-de-Sá P; Ribeiro JA
Neuroscience; 1996 Jul; 73(1):85-92. PubMed ID: 8783232
[TBL] [Abstract][Full Text] [Related]
15. Optimization of the local inhibition of intestinal adenosine deaminase (ADA) by erythro-9-(2-hydroxy-3-nonyl)adenine: enhanced oral delivery of an ADA-activated prodrug for anti-HIV therapy.
Singhal D; Anderson BD
J Pharm Sci; 1998 May; 87(5):578-85. PubMed ID: 9572908
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of brain adenosine deaminase by 2'-deoxycoformycin and erythro-9-(2-hydroxy-3-nonyl) adenine.
Skolnick P; Nimitkitpaisan Y; Stalvey L; Daly JW
J Neurochem; 1978 Jun; 30(6):1479-82. PubMed ID: 670988
[No Abstract] [Full Text] [Related]
17. Adenosine deaminase inhibitors. Conversion of a single chiral synthon into erythro- and threo-9-(2-hydroxy-3-nonyl)adenines.
Bastian G; Bessodes M; Panzica RP; Abushanab E; Chen SF; Stoeckler JD; Parks RE
J Med Chem; 1981 Dec; 24(12):1383-5. PubMed ID: 7310814
[No Abstract] [Full Text] [Related]
18. Adenosine deaminase inhibitors: synthesis and structure-activity relationships of imidazole analogues of erythro-9-(2-hydroxy-3-nonyl)adenine.
Cristalli G; Eleuteri A; Franchetti P; Grifantini M; Vittori S; Lupidi G
J Med Chem; 1991 Mar; 34(3):1187-92. PubMed ID: 2002459
[TBL] [Abstract][Full Text] [Related]
19. Niacin prevents DNA strand breakage by adenosine deaminase inhibitors.
Weitberg AB; Corvese D
Biochem Biophys Res Commun; 1990 Mar; 167(2):514-9. PubMed ID: 2322239
[TBL] [Abstract][Full Text] [Related]
20. Modifications of flexible nonyl chain and nucleobase head group of (+)-erythro-9-(2's-hydroxy-3's-nonyl)adenine [(+)-EHNA] as adenosine deaminase inhibitors.
Kandalkar SR; Ramaiah PA; Joshi M; Wavhal A; Waman Y; Raje AA; Tambe A; Ansari S; De S; Palle VP; Mookhtiar KA; Deshpande AM; Barawkar DA
Bioorg Med Chem; 2017 Oct; 25(20):5799-5819. PubMed ID: 28951094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
